Aldosterone: Role in the Cardiometabolic Syndrome and Resistant Hypertension

Progress in Cardiovascular Diseases

Volumn 52, Issue 5, 2010, Pages 401-409

  Whaley Connell, Adam ^a   Johnson, Megan S ^a   Sowers, James R ^a  

^a University of Missouri   (United States)

Author keywords

Aldosterone; Cardiometabolic syndrome; Hypertension; Insulin resistance

Indexed keywords

ALDOSTERONE; GLUCOCORTICOID; GLUCOSE; INSULIN; MINERALOCORTICOID RECEPTOR; OXYGEN RADICAL;

ADIPOSE TISSUE; ALBUMINURIA; ALDOSTERONE BLOOD LEVEL; ARTICLE; CARDIOMETABOLIC SYNDROME; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DISEASE COURSE; DISEASE RESISTANCE; DYSLIPIDEMIA; ENDOTHELIUM; GLUCOSE UTILIZATION; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; LIVER; NERVOUS TISSUE; OBESITY; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PREVALENCE; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SYNDROME; VASODILATATION; ZONA GLOMERULOSA;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG RESISTANCE; ENDOTHELIUM, VASCULAR; HEART; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; INSULIN RESISTANCE; KIDNEY; METABOLIC SYNDROME X; RECEPTORS, MINERALOCORTICOID; RISK FACTORS; SIGNAL TRANSDUCTION; TREATMENT FAILURE;

EID: 77649291571     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2009.12.004     Document Type: Article

References (77)

1. Ginsberg H.N., and MacCallum P.R. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr. 4 (2009) 113-119
2. Park Y.W., Zhu S., Palaniappan L., et al. The metabolic syndrome: prevalence and associated risk factor findings in the US Population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 163 (2003) 427-436
3. Malik S., Wong N.D., Franklin S.S., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110 (2004) 1245-1250
4. Manrique C., Lastra G., Whaley-Connell A., et al. Hypertension and the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 7 (2005) 471-476
5. Sowers J.R. Obesity as a cardiovascular risk factor. Am J Med 115 Supp 8A (2003) 37S-41S
6. Van Gaal L.F., Mertens I.L., and DeBlock C.E. Mechanisms linking obesity with cardiovascular disease. Nature 444 (2006) 875-880
7. Sowers J.R. Metabolic risk factors and renal disease. Kidney Int 71 (2007) 719-720
8. Cooper S.A., Whaley-Connell A., Habibi J., et al. Renin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 293 (2007) H2009-2023
9. Ogden C.L., Carroll M.D., Curtin L.R., et al. Prevalence of overweight and obesity in the United States,1999-2004. JAMA 295 (2006) 1549-1555
10. Wei Y., Chen K., Whaley-Connell A.T., et al. Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. Am J Physiol Regul Integr Comp Physiol 294 (2008) R673-R680
11. Lastra G., Whaley-Connell A., Manrique C., et al. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2) rat. Am J Physiol Endocrinol Metab 295 (2008) E110-E116
12. Bakris G.L., Sowers J.R., and American Society of Hypertension Writing Group. ASH position paper: treatment of hypertension in patients with diabetes-an update. J Clin Hypertens (Greenwich). 10 (2008) 707-713
13. Hayden M.R., Whaley-Connell A., and Sowers J.R. Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy. Am J Nephrol 25 (2005) 553-569
14. Sowers J.R., Whaley-Connell A., and Epstein M. The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 150 (2009) 776-783
15. Bomback A.S., and Klemmer P.J. Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease. Am J Nephrol 30 (2009) 140-146
16. Schiffrin E.L. Effects of aldosterone on the vasculature. Hypertension 47 (2006) 312-318
17. Wei Y., Whaley-Connell A.T., Habibi J., et al. Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension 53 (2009) 158-165
18. Hitomi H., Kiyomoto H., Nishiyama A., et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 50 (2007) 750-755
19. Brown N.J. Aldosterone and vascular inflammation. Hypertension 51 (2008) 161-167
20. Gaddam K.K., Nishizaka M.K., Pratt-Ubunama M.N., et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 168 (2008) 1159-1164
21. Whaley-Connell A., Habibi J., Wei Y., et al. Mineralcorticoid receptor antagonism attenuates kidney renin-angiotensin-aldosterone system mediated filtration barrier remodeling in the transgenic Ren2 rat. Am J of Physiol Renal Physiol 296 (2009) F1013-F1022
22. Nagase M., Yoshida S., Shibata S., et al. Enhanced aldosterone signaling in the early nephrology of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 17 (2006) 3438-3446
23. Bochud M., Nussberger J., Bovet P., et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48 (2006) 239-245
24. Fallo F., Veglio F., Bertello C., et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrin Metab 91 (2006) 454-459
25. Fallo F., Mea P.D., Sonino N., et al. Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens 20 (2007) 855-861
26. Giacchetti G., Ronconi V., Turchi F., et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 25 (2007) 177-186
27. Catena C., Lapenna R., Baroselli S., et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 91 (2006) 3457-3463
28. Ehrhart-Bornstein M., Arakelyan K., Krug A.W., et al. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res 30 (2004) 865-870
29. Rondinone C.M., Rodbard D., and Baker M.E. Aldosterone stimulated differentiation of mouse 3T3-L1 cells into adipocytes. Endocrinology 132 (1993) 2421-2426
30. Caprio M., Feve B., Claes A., et al. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 21 (2007) 2185-2194
31. Guo C., Ricchiuti V., Lian B.Q., et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 117 (2008) 2253-2261
32. Campión J., Lahera V., Cachofeiro V., et al. In vivo tissue specific modulation of rat insulin receptor gene expression in an experimental model of mineralocorticoid excess. Mol Cell Biochem 185 (1998) 177-182
33. Mosso L.M., Carvajal C.A., and Fardella C.E. A possible association between primary aldosteronism and lower [beta]-cell function. J Hypertens 26 (2008) 609-610
34. Hayden M.R., and Sowers J.R. Pancreatic renin-angiotensin-aldosterone system in the cardiometabolic syndrome and type-2 diabetes. J Cardiometab Synd 3 (2008) 129-131
35. Calhoun D.A., Nishizaka M.K., Zaman M.A., et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40 (2002) 892-896
36. Strauch B., Zelinka T., Hampf M., et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in Central Europe region. J Hum Hypertens 17 (2003) 349-352
37. Eide I.K., Torjesen P.A., Drolsum A., et al. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 22 (2004) 2217-2226
38. Kidambi S., Kotchen J.M., Grim C.E., et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 49 (2007) 704-711
39. Douma S., Petidis K., Doumas M., et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 371 (2008) 1921-1926
40. Strauch B., Zelinka T., Hampf M., et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 17 (2003) 349-352
41. Rossi G.P., Bernini G., Caliumi C., et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48 (2006) 2293-2300
42. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 117 (2008) e510-e526
43. Pimenta E., and Calhoun D.A. Aldosterone and metabolic dysfunction: an unresolved issue. Hypertension 53 (2009) 585-586
44. Duprez D.A., Bauwens F.R., De Buyzere M.L., et al. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol 71 (1993) 17A-20A
45. Schunkert H., Hense H.W., Muscholl M., et al. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart 77 (1997) 24-31
46. Vasan R.S., Evans J.C., Larson M.G., et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351 (2004) 33-41
47. Newton-Cheh C., Guo C.Y., Gona P., et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 49 (2007) 846-856
48. Milliez P., Girerd X., Plouin P.F., et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45 (2005) 1243-1248
49. Ronconi V., Turchi F., Rilli S., et al. Metabolic syndrome in primary aldosteronism and essential hypertension: relationship to adiponectin gene variants. Nutr Metab Cardiovasc Dis (2009) [Epub ahead of print]
50. Chen S.Y., Bhargava A., Mastroberardino L., et al. Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci U S A 96 (1999) 2514-2519
51. Shigaev A., Asher C., Latter H., et al. Regulation of sgk by aldosterone and its effects on the epithelial Na(+) channel. Am J Physiol Renal Physiol 278 (2000) F613-F619
52. Sun Y., Zhang J., Lu L., et al. Aldosterone-induced inflammation in the rat heart : role of oxidative stress. Am J Pathol 161 (2002) 1773-1781
53. Zhao W., Ahokas R.A., Weber K.T., et al. ANG II-induced cardiac molecular and cellular events: role of aldosterone. Am J Physiol Heart Circ Physiol 291 (2006) H336-H343
54. Miyata Y., Muto S., and Kusano E. Mechanisms for nongenomic and genomic effects of aldosterone on Na+/H+ exchange in vascular smooth muscle cells. J Hypertens 23 (2005) 2237-2250
55. Ebata S., Muto S., Okada K., et al. Aldosterone activates Na+/H+ exchange in vascular smooth muscle cells by nongenomic and genomic mechanisms. Kidney Int 56 (1999) 1400-1412
56. Gomez-Sanchez E.P. Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease. Curr Opin Nephrol Hypertens 13 (2004) 191-196
57. Sakai R.R., McEwen B.S., Fluharty S.J., et al. The amygdala: site of genomic and nongenomic arousal of aldosterone-induced sodium intake. Kidney Int 57 (2000) 1337-1345
58. Zhang Z.H., Wei S.G., Francis J., et al. Cardiovascular and renal sympathetic activation by blood-borne TNF-alpha in rat: the role of central prostaglandins. Am J Physiol Regul Integr Comp Physiol 284 (2003) R916-R927
59. Yu Y., Wei S.G., Zhang Z.H., et al. Does aldosterone upregulate the brain rennin-angiotensin system in rats with heart failure?. Hypertension 51 (2008) 727-733
60. Gomez-Sanchez E.P., Ahmad N., Romero D.G., et al. Is aldosterone synthesized within the rat brain?. Am J Physiol Endocrinol Metab 288 (2005) E342-E346
61. Huang B.S., Amin M.S., and Leenen F.H. The central role of the brain in salt-sensitive hypertension. Curr Opin Cardiol 21 (2006) 295-304
62. Choi E.Y., Ha J.W., Yoon S.J., et al. Increased plasma aldosterone-to-renin ratio is associated with impaired left ventricular longitudinal functional reserve in patients with uncomplicated hypertension. J Am Soc Echocardiogr 21 (2008) 251-256
63. Galetta F., Bernini G., Franzoni F., et al. Cardiac remodeling in patients with primary aldosteronism. J Endocrinol Invest (2009) [Epub ahead of print]
64. Li R., Richey P.A., DiSessa T.G., et al. Blood aldosterone-to-renin ratio, ambulatory blood pressure, and left ventricular mass in children. J Pediatr 155 (2009) 170-175
65. Harada E., Yoshimura M., Yasue H., et al. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 104 (2001) 137-139
66. Rocha R., Martin-Berger C.L., Yang P., et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143 (2002) 4828-4836
67. Johar S., Cave A.C., Narayanapanicker A., et al. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 20 (2006) 1546-1548
68. Hirono Y., Yoshimoto T., Suzuki N., et al. Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. Endocrinology 148 (2007) 1688-1696
69. Stas S., Whaley-Connell A., Habibi J., et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 148 (2007) 3773-3780
70. Furumatsu Y., Nagasawa Y., Tomida K., et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 31 (2008) 59-67
71. Sato A., Hayashi K., and Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 18 (2005) 44-49
72. Sato A., Saruta T., and Funder J.W. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res 29 (2006) 211-216
73. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 119 (2006) 912-919
74. Bauersachs J., and Fraccarollo D. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure. Minerva Cardioangiol 51 (2003) 155-164
75. Takeda Y., Zhu A., Yoneda T., et al. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats. Am J Hypertens 20 (2007) 1119-1124
76. Jansen P.M., Danser A.H., Imholz B.P., et al. Aldosterone-receptor antagonism in hypertension. J Hypertens 27 (2009) 680-691
77. Tylicki L., Rutkowski P., Renke M., et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 52 (2008) 486-493